<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Desligniere E</submitter><funding>Dutch Research Council (NWO)</funding><pagination>101454</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11999443</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>33(2)</volume><pubmed_abstract>The impressive success of mRNA-based vaccines to combat COVID-19 has encouraged biopharmaceutical companies to invest in broader applications of alike vaccines for various diseases. Analytical approaches must keep pace to support this surge in the development of mRNA-based therapies. Intact mass analysis of mid- to large mRNA molecules (>1,000 nt) poses significant analytical challenges due to mRNA size, heterogeneity, and instability. Here, we demonstrate how single-particle Orbitrap-based charge detection mass spectrometry (CDMS) and mass photometry (MP) approaches can rapidly measure the mass of various intact high-mass capped mRNAs, up to 9,400 nt (∼3 MDa) in size. While ensemble MS yielded approximate masses for mRNAs &lt;2,000 nt, it failed to provide information on samples of longer se</pubmed_abstract><journal>Molecular therapy. Methods &amp; clinical development</journal><pubmed_title>Characterization of intact mRNA-based therapeutics by charge detection mass spectrometry and mass photometry.</pubmed_title><pmcid>PMC11999443</pmcid><funding_grant_id>SPI.2017.028</funding_grant_id><pubmed_authors>Heck AJR</pubmed_authors><pubmed_authors>Barnes LF</pubmed_authors><pubmed_authors>Powers TW</pubmed_authors><pubmed_authors>Friese OV</pubmed_authors><pubmed_authors>Desligniere E</pubmed_authors></additional><is_claimable>false</is_claimable><name>Characterization of intact mRNA-based therapeutics by charge detection mass spectrometry and mass photometry.</name><description>The impressive success of mRNA-based vaccines to combat COVID-19 has encouraged biopharmaceutical companies to invest in broader applications of alike vaccines for various diseases. Analytical approaches must keep pace to support this surge in the development of mRNA-based therapies. Intact mass analysis of mid- to large mRNA molecules (>1,000 nt) poses significant analytical challenges due to mRNA size, heterogeneity, and instability. Here, we demonstrate how single-particle Orbitrap-based charge detection mass spectrometry (CDMS) and mass photometry (MP) approaches can rapidly measure the mass of various intact high-mass capped mRNAs, up to 9,400 nt (∼3 MDa) in size. While ensemble MS yielded approximate masses for mRNAs &lt;2,000 nt, it failed to provide information on samples of longer se</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Jun</publication><modification>2025-07-07T03:10:13.694Z</modification><creation>2025-07-07T03:10:13.694Z</creation></dates><accession>S-EPMC11999443</accession><cross_references><pubmed>40236497</pubmed><doi>10.1016/j.omtm.2025.101454</doi></cross_references></HashMap>